Single and multi-component biguanide-based microbicides
单组分和多组分双胍类杀菌剂
基本信息
- 批准号:7492524
- 负责人:
- 金额:$ 14.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-30 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAntiviral AgentsArtsBiguanidesBindingBiochemicalBiologicalBiological AssayBiological ModelsCCR5 geneCXCR4 ReceptorsCervicalClassClassificationClinicalClinical TrialsCommunicationCompatibleCoupledDailyDataDatabasesDevelopmentDrug CombinationsDrug FormulationsDrug KineticsEvaluationFeedbackGoalsHIV-1Immune responseIn VitroInfectionInorganic SulfatesIntellectual PropertyLeadLocal MicrobicidesMaintenanceMedicineMolecularMusMutateNatureOnline SystemsPharmaceutical PreparationsPolyethylenePolyethylenesPositioning AttributePreparationProductionProgress ReportsPropertyProtocols documentationPublicationsRelative (related person)ResearchResearch PersonnelResearch Project GrantsSchemeSiteStagingStructureSystemTestingTherapeutic IndexTimeToxic effectTreatment ProtocolsU-Series Cooperative AgreementsUnspecified or Sulfate Ion SulfatesVaginaVaginal GelVirusVirus ReplicationViscosityWorkbasecollegecommercializationcomputerized data processingdesigndrug discoveryexperimental analysishuman subjecthuman tissuein vivoin vivo Modelinhibitor/antagonistmembermicrobicidemolecular modelingpre-clinicalpressureprogramsscaffoldsoundtransmission process
项目摘要
DESCRIPTION (provided by applicant): The quasi species nature of a human immunodeficiency virus type 1 (HIV-1) infection coupled with the virus's ability to rapidly mutate away from selective drug pressure has led to the use of multiple drugs in combination as the accepted paradigm for treating systemic HIV-1 infections. Therefore it is quite likely that to obtain a safe and effective anti-HIV-1 microbicide a similar approach will be employed. The long-term objectives this "Integrated preclinical program for topical microbicides", is to provide data that will help justify the clinical development and commercialization of polyethylene-hexamethylene biguanide (PEHMB or PEHMB-derived product) alone or as part of a combination regimen. PEHMB is a potent inhibitor of HIV-1 with minimal toxicity yielding a therapeutic index >1400. Mechanism of action studies has provided evidence that PEHMB's antiviral activity is due to interference with virus binding to the cellular receptors CXCR4 and CCR5. In addition, large-scale production of PEHMB is estimated to be extremely inexpensive (dollars/kg), and we have found PEHMB to be extremely compatible with and stable in normal vaginal gel viscosity building agents. All of these attributes are promising enough to warrant further preclinical evaluation of this compound. In preliminary studies we have also combined PEHMB with members of other classes of putative anti-HIV-1 microbicides including a sulfated dendrimer developed by Dr. Shengrund at Penn State College of Medicine. We propose in this Program to identify the best PEHMB-based combination of drug candidates to maximize the suppressive effect on HIV-1 transmission. This program will involve three research projects integrated into one program. Project I will continue to refine antiviral efficacy and cellular toxicity parameters of the PEHMB scaffold based on computational approaches coupled to iterative rounds of feedback from our biochemical and biological assay systems. In addition, in Project I we will purify PEHMB, work to understand its structure, perform pharmacokinetic and murine toxicity studies as well as begin pre-formulation and formulation work for use in in vivo experimentation and manufacturing schemes. Project II will have the important task of assessing the relative toxicity of PEHMB utilizing both in vitro and in vivo model systems while at the same time provide the intellectual lead in our understanding of the molecular mechanism(s) b y which the PBG class of compounds inhibit virus replication and elicit cellular toxicity. Project II will also examine the impact of microbicides on the intra-vaginal and cervical immune response utilizing well-defined animal models. In Project Ill, we will use state of the art in vitro and in vivo model systems to profile the antiviral efficacy of our lead compound or combination. Project III will examine preformulation parameters, and test the efficacy of the formulated products in vitro including systematic studies to develop combination microbicides based on PEHMB and then test these formulated combinations using xenograph model systems developed by the investigators. All of the efforts outlined in the three projects are focused on providing information needed to move PEHMB and its viable combinations from a pre-clinical to a clinical stage in the drug discovery/development pipeline, with the goal of offering a new class of compounds with specific mode of action distinct from other compounds currently in clinical trials.
描述(由申请人提供):人类免疫缺陷病毒 1 型 (HIV-1) 感染的准物种性质,加上该病毒能够在选择性药物压力下快速突变的能力,导致多种药物联合使用成为公认的治疗方法。治疗全身性 HIV-1 感染的范例。因此,为了获得安全有效的抗HIV-1杀微生物剂,很可能会采用类似的方法。该“局部杀菌剂临床前综合计划”的长期目标是提供数据,帮助证明聚乙烯-六亚甲基双胍(PEHMB 或 PEHMB 衍生产品)单独或作为联合方案的一部分的临床开发和商业化的合理性。 PEHMB 是一种有效的 HIV-1 抑制剂,毒性极小,治疗指数 >1400。作用机制研究提供的证据表明,PEHMB 的抗病毒活性是由于干扰病毒与细胞受体 CXCR4 和 CCR5 的结合。此外,PEHMB 的大规模生产估计极其便宜(美元/千克),而且我们发现 PEHMB 与普通阴道凝胶增粘剂极其相容且稳定。所有这些属性都足以保证对该化合物进行进一步的临床前评估。在初步研究中,我们还将 PEHMB 与其他类别的假定抗 HIV-1 杀菌剂的成员结合起来,包括宾夕法尼亚州立大学医学院的 Shengrund 博士开发的硫酸化树枝状聚合物。我们在此计划中建议确定基于 PEHMB 的最佳候选药物组合,以最大限度地发挥对 HIV-1 传播的抑制作用。该计划将把三个研究项目整合为一个计划。项目 I 将基于计算方法以及来自我们的生化和生物测定系统的迭代反馈,继续完善 PEHMB 支架的抗病毒功效和细胞毒性参数。此外,在项目一中,我们将纯化PEHMB,努力了解其结构,进行药代动力学和小鼠毒性研究,并开始用于体内实验和制造方案的预配制和配制工作。项目 II 的重要任务是利用体外和体内模型系统评估 PEHMB 的相对毒性,同时为我们理解 PBG 类化合物抑制的分子机制提供智力指导。病毒复制并引起细胞毒性。项目 II 还将利用明确的动物模型研究杀菌剂对阴道内和宫颈免疫反应的影响。在项目III中,我们将使用最先进的体外和体内模型系统来分析我们的先导化合物或组合的抗病毒功效。项目III将检查预配制参数,并在体外测试配制产品的功效,包括系统研究开发基于PEHMB的组合杀菌剂,然后使用研究人员开发的异种模型系统测试这些配制的组合。这三个项目中概述的所有工作都集中于提供将 PEHMB 及其可行组合从药物发现/开发管道中的临床前阶段转移到临床阶段所需的信息,目标是提供具有以下特性的新型化合物:与目前处于临床试验中的其他化合物不同的特定作用模式。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety.
- DOI:10.1186/2050-6511-13-9
- 发表时间:2012-10-01
- 期刊:
- 影响因子:2.9
- 作者:Lozenski K;Ownbey R;Wigdahl B;Kish-Catalone T;Krebs FC
- 通讯作者:Krebs FC
A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection.
- DOI:10.1155/2010/548749
- 发表时间:2010
- 期刊:
- 影响因子:0
- 作者:Pirrone V;Passic S;Wigdahl B;Rando RF;Labib M;Krebs FC
- 通讯作者:Krebs FC
Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1.
- DOI:10.1186/1743-422x-9-33
- 发表时间:2012-01-26
- 期刊:
- 影响因子:4.8
- 作者:Pirrone V;Passic S;Wigdahl B;Krebs FC
- 通讯作者:Krebs FC
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MOHAMED E LABIB其他文献
MOHAMED E LABIB的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MOHAMED E LABIB', 18)}}的其他基金
Novel hand hygiene product to remove Clostridioides difficile spores
新型手部卫生产品可去除艰难梭菌孢子
- 批准号:
10603462 - 财政年份:2023
- 资助金额:
$ 14.81万 - 项目类别:
Novel outside-in dialyzer with long filter life and reduced anticoagulation therapies
新型由外向内透析器,过滤器寿命长,并减少抗凝治疗
- 批准号:
10264173 - 财政年份:2020
- 资助金额:
$ 14.81万 - 项目类别:
Improved cleaning technology for reducing risk of transmitting infection in endoscopy.
改进的清洁技术可降低内窥镜检查中传播感染的风险。
- 批准号:
9759757 - 财政年份:2017
- 资助金额:
$ 14.81万 - 项目类别:
A Novel Device for Managing Hypervolemia in CHF Patients
一种治疗慢性心力衰竭患者高血容量的新型装置
- 批准号:
8131110 - 财政年份:2010
- 资助金额:
$ 14.81万 - 项目类别:
A Novel Device for Managing Hypervolemia in CHF Patients
一种治疗慢性心力衰竭患者高血容量的新型装置
- 批准号:
8002223 - 财政年份:2010
- 资助金额:
$ 14.81万 - 项目类别:
Microbicide delivery system to target lymphoid organs
靶向淋巴器官的杀微生物剂输送系统
- 批准号:
7936982 - 财政年份:2009
- 资助金额:
$ 14.81万 - 项目类别:
Microbicide delivery system to target lymphoid organs
靶向淋巴器官的杀微生物剂输送系统
- 批准号:
8309687 - 财政年份:2009
- 资助金额:
$ 14.81万 - 项目类别:
Microbicide delivery system to target lymphoid organs
靶向淋巴器官的杀微生物剂输送系统
- 批准号:
8322610 - 财政年份:2009
- 资助金额:
$ 14.81万 - 项目类别:
Microbicide delivery system to target lymphoid organs
靶向淋巴器官的杀微生物剂输送系统
- 批准号:
7669867 - 财政年份:2009
- 资助金额:
$ 14.81万 - 项目类别:
Microbicide delivery system to target lymphoid organs
靶向淋巴器官的杀微生物剂输送系统
- 批准号:
8523751 - 财政年份:2009
- 资助金额:
$ 14.81万 - 项目类别:
相似国自然基金
基于激发植物免疫为导向的嘧啶酮类高效抗病毒剂设计合成及作用机制研究
- 批准号:21807037
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
云南地方晾晒烟中的内源性抗烟草花叶病毒活性成分研究
- 批准号:31860100
- 批准年份:2018
- 资助金额:41.0 万元
- 项目类别:地区科学基金项目
基于kealiinine类海洋生物碱的新型抗病毒剂的设计合成、构效关系及作用机制研究
- 批准号:21772145
- 批准年份:2017
- 资助金额:64.0 万元
- 项目类别:面上项目
两种植物中抗烟草花叶病毒先导化合物的结构优化、构效关系及作用机制研究
- 批准号:31760089
- 批准年份:2017
- 资助金额:38.0 万元
- 项目类别:地区科学基金项目
生态农药的分子设计与作用机制
- 批准号:21732002
- 批准年份:2017
- 资助金额:300.0 万元
- 项目类别:重点项目
相似海外基金
Molecular Virology and Systems Biology Screening Core
分子病毒学和系统生物学筛选核心
- 批准号:
8013207 - 财政年份:2010
- 资助金额:
$ 14.81万 - 项目类别:
Development of drugs that target the M2 proton channel from the influenza A Virus
开发针对甲型流感病毒 M2 质子通道的药物
- 批准号:
7813771 - 财政年份:2008
- 资助金额:
$ 14.81万 - 项目类别: